Carrier screening in the reproductive setting—Are there medical implications for the heterozygote?—A guide for clinicians
Pregnancy · 2026-05 · 2 (3)
DOI: 10.1002/pmf2.70280 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pregnancy, online erschienen am 09.04.2026. Verfasst von Emily B Rosenfeld und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Maternal-Fetal Medicine Department of Obstetrics Gynecology, and Reproductive Sciences Rutgers Robert Wood Johnson Medical School New Bru…. Die Arbeit nennt 559 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Carrier screening for genetic conditions performed preconception or during pregnancy allows identification of fetal risk for inherited autosomal recessive and X‐linked conditions. The goal is to identify at‐risk patients/couples and offer them reproductive options such as preimplantation genetic diagnosis, prenatal testing, or targeted newborn testing. Although individuals are expected to be carriers for autosomal recessive conditions, most couples are not carriers of the same condition. The traditional understanding is that carriers do not exhibit symptoms of disease. However, recent studies have shown that there may be clinical implications for medical management of some conditions in the carrier state, especially in the obstetrical setting. One study showed that 9% of patients who underwent large carrier screening panels were carriers for a condition with clinical implications in the heterozygous state. It is estimated that 2.5% of females are heterozygous for a condition that impacts their medical management during pregnancy. Obstetric clinicians who often interpret carrier screen results must be aware of the potential clinical implications and incorporate this information into their counseling and management plans. In this review, we examined three large panethnic, commercially available carrier screening panels that collectively cover 818 genes. We found that 112 (13.7%) of the conditions have definite or strong implications in the carrier state, and another 100 (12.2%) have moderate or limited evidence of implications in the carrier state. Of the identified genes, 19 may have an impact during pregnancy. This information, if used to guide clinicians on conditions that require further counseling and evaluation, may improve outcomes when incorporated into obstetric practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Maternal-Fetal Medicine Department of Obstetrics Gynecology, and Reproductive Sciences Rutgers Robert Wood Johnson Medical School New Brunswick New Jersey USA.
- Division of Biostatistics and Epidemiology Department of Obstetrics Gynecology, and Reproductive Sciences Rutgers Robert Wood Johnson Medical School New Brunswick New Jersey USA.
- Genetic Counseling Master's Program Rutgers University Piscataway New Jersey USA.
- Department of Obstetrics and Gynecology Morristown Medical Center Morristown New Jersey USA.
- Division of Genetics Department of Pediatrics Rutgers Robert Wood Johnson Medical School New Brunswick New Jersey USA.
- Division of Maternal-Fetal Medicine Department of Obstetrics and Gynecology NYU Grossman School of Medicine New York New York USA.
ORCID-Profile: Emily B Rosenfeld, Milen Velinov
Zitieren
APA
Rosenfeld, E. B., Kasatkin, N., Yu, B. L., Velinov, M., Brandt, J. S., & Ashkinadze, E. (2026). Carrier screening in the reproductive setting—Are there medical implications for the heterozygote?—A guide for clinicians. Pregnancy, 2(3). https://doi.org/10.1002/pmf2.70280
Vancouver
Rosenfeld EB, Kasatkin N, Yu BL, Velinov M, Brandt JS, Ashkinadze E. Carrier screening in the reproductive setting—Are there medical implications for the heterozygote?—A guide for clinicians. Pregnancy. 2026;2(3). doi:10.1002/pmf2.70280
BibTeX
@article{Rosenfeld2026,
author = {Rosenfeld, Emily B and Kasatkin, Nicole and Yu, Bi Liu and Velinov, Milen and Brandt, Justin S and Ashkinadze, Elena},
title = {Carrier screening in the reproductive setting—Are there medical implications for the heterozygote?—A guide for clinicians},
journal = {Pregnancy},
year = {2026},
volume = {2},
number = {3},
doi = {10.1002/pmf2.70280}
}
EUVIMED